100 related articles for article (PubMed ID: 32359131)
1. Lifetime health care costs of oropharyngeal cancer for commercially insured patients in the United States.
Wu CF; Lairson DR; Dahlstrom KR; Fokom Domgue J; Fu S; Sturgis EM; Chan W
Head Neck; 2020 Sep; 42(9):2321-2329. PubMed ID: 32359131
[TBL] [Abstract][Full Text] [Related]
2. Oral Cancer Prevalence, Mortality, and Costs in Medicaid and Commercial Insurance Claims Data.
Tranby EP; Heaton LJ; Tomar SL; Kelly AL; Fager GL; Backley M; Frantsve-Hawley J
Cancer Epidemiol Biomarkers Prev; 2022 Sep; 31(9):1849-1857. PubMed ID: 35732291
[TBL] [Abstract][Full Text] [Related]
3. Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States.
Wu CF; Xu L; Fu S; Peng HL; Messick CA; Lairson DR
J Manag Care Spec Pharm; 2018 Nov; 24(11):1156-1164. PubMed ID: 30362917
[TBL] [Abstract][Full Text] [Related]
4. Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population.
Shah R; Corman S; Shah A; Kebede N; Nwankwo C
J Med Econ; 2021; 24(1):1221-1230. PubMed ID: 34686073
[TBL] [Abstract][Full Text] [Related]
5. Direct medical cost of oropharyngeal cancer among patients insured by Medicaid in Texas.
Zhao B; Fu S; Wu CF; Dahlstrom KR; Fokom Domgue J; Tam S; Xu L; Sturgis EM; Lairson DR
Oral Oncol; 2019 Sep; 96():21-26. PubMed ID: 31422209
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States.
Korsnes JS; Goodwin BB; Murray M; Candrilli SD
Ann Pharmacother; 2016 Dec; 50(12):989-1000. PubMed ID: 27439947
[TBL] [Abstract][Full Text] [Related]
8. Medical Care Cost of Oropharyngeal Cancer among Texas Patients.
Lairson DR; Wu CF; Chan W; Dahlstrom KR; Tam S; Sturgis EM
Cancer Epidemiol Biomarkers Prev; 2017 Sep; 26(9):1443-1449. PubMed ID: 28838945
[No Abstract] [Full Text] [Related]
9. The cost of oropharyngeal cancer in England: A retrospective hospital data analysis.
Keeping ST; Tempest MJ; Stephens SJ; Carroll SM; Simcock R; Jones TM; Shaw R
Clin Otolaryngol; 2018 Feb; 43(1):223-229. PubMed ID: 28734109
[TBL] [Abstract][Full Text] [Related]
10. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
11. Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions.
Bagalman E; Muser E; Choi JC; Durden E; Macfadden W; Haskins JT; Dirani R
Clin Ther; 2011 Oct; 33(10):1381-1390.e4. PubMed ID: 22000656
[TBL] [Abstract][Full Text] [Related]
12. Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population.
Kern DM; Mellström C; Hunt PR; Tunceli O; Wu B; Westergaard M; Hammar N
Curr Med Res Opin; 2016; 32(4):703-11. PubMed ID: 26709864
[TBL] [Abstract][Full Text] [Related]
13. The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States.
Rice JB; White AG; Galebach P; Korenblat KM; Wagh A; Lovelace B; Wan GJ; Jamil K
Curr Med Res Opin; 2017 Aug; 33(8):1473-1480. PubMed ID: 28509578
[TBL] [Abstract][Full Text] [Related]
14. Insurance Status as a Predictor of Treatment in Human Papillomavirus Positive Oropharyngeal Cancer.
Berger MH; Yasaka TM; Haidar YM; Kuan EC; Tjoa T
Laryngoscope; 2021 Apr; 131(4):776-781. PubMed ID: 32790156
[TBL] [Abstract][Full Text] [Related]
15. Drivers of excess costs of opioid abuse among a commercially insured population.
Scarpati LM; Kirson NY; Zichlin ML; Jia ZB; Birnbaum HG; Howard JC
Am J Manag Care; 2017 May; 23(5):276-282. PubMed ID: 28738684
[TBL] [Abstract][Full Text] [Related]
16. Association of Transoral Robotic Surgery With Short-term and Long-term Outcomes and Costs of Care in Oropharyngeal Cancer Surgery.
Motz K; Chang HY; Quon H; Richmon J; Eisele DW; Gourin CG
JAMA Otolaryngol Head Neck Surg; 2017 Jun; 143(6):580-588. PubMed ID: 28358930
[TBL] [Abstract][Full Text] [Related]
17. Societal cost of oropharyngeal cancer by human papillomavirus status, cancer stage, and subsite.
Silfverschiöld M; Sjövall J; Wennerberg J; Östensson E; Greiff L
PLoS One; 2019; 14(7):e0220534. PubMed ID: 31356646
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of diagnosed opioid abuse among commercially insured individuals.
Rice JB; Kirson NY; Shei A; Enloe CJ; Cummings AK; Birnbaum HG; Holly P; Ben-Joseph R
Postgrad Med; 2014 Jul; 126(4):53-8. PubMed ID: 25141243
[TBL] [Abstract][Full Text] [Related]
19. Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States.
Lairson DR; Wu CF; Chan W; Fu S; Hoffman KE; Pettaway CA
Urol Oncol; 2019 Apr; 37(4):294.e17-294.e25. PubMed ID: 30660492
[TBL] [Abstract][Full Text] [Related]
20. The lifetime cost of hepatocellular carcinoma : a claims data analysis from a medical centre in Taiwan.
Lang HC; Wu JC; Yen SH; Lan CF; Wu SL
Appl Health Econ Health Policy; 2008; 6(1):55-65. PubMed ID: 18774870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
